BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Inflectra is a prescription medication approved by the Food and Drug Administration (FDA) for the treatment of active ankylosing spondylitis and psoriatic arthritis, chronic severe plaque psoriasis, and moderately to severely active cases of ulcerative colitis, Crohn’s disease (adult and pediatric), and rheumatoid arthritis (in combination with Methotrexate). Inflectra may be referred to by its drug name, Infliximab-dyyb.
Inflectra is a biosimilar of Remicade. As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product.
Inflectra is an immunomodulator, or drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Inflectra is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Inflectra binds to TNF-α and prevents it from signaling the immune system to attack.
How do I take it?
Inflectra is administered as an intravenous infusion in a medical setting every six or eight weeks after initial loading doses.
Inflectra is available in vial form.
The FDA-approved label for Inflectra lists common side effects including headache, cold and flu symptoms, infusion reactions, and abdominal pain.
Rare but serious side effects listed for Inflectra include blood disorders, severe infections, increased risk for certain types of cancer, liver or heart failure, severe allergic reactions, and the development of lupus-like syndrome or demyelinating disease such as multiple sclerosis.
For answers to frequently asked questions about exposure to Infliximab during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Inflectra – Pfizer